BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Custirsen sodium: Phase III ongoing

OncoGenex reported in its 2Q11 earnings that data on the primary endpoint from the double-blind, placebo-controlled international Phase III SATURN trial of custirsen plus docetaxel/prednisone as second-line chemotherapy will be delayed to 4Q13 from 2Q13 due to slow enrollment. Earlier this year, the company submitted a revised SPA to FDA for the trial to expand the...

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >